Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma

Blood

Volumn 119, Issue 10, 2012, Pages 2302-2309

  Koduru, Srinivas ^a   Wong, Ellice ^a   Strowig, Till ^a   Sundaram, Ranjini ^a   Zhang, Lin ^a   Strout, Matthew P ^a   Flavell, Richard A ^a,b   Schatz, David G ^a,b   Dhodapkar, Kavita M ^a   Dhodapkar, Madhav V ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ACTIVATION INDUCED CYTIDINE DEAMINASE; CD209 ANTIGEN; OSTEOCLAST DIFFERENTIATION FACTOR; SYNAPTOTAGMIN I; SYNDECAN 1;

ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL INFILTRATION; CELL INTERACTION; CONTROLLED STUDY; DENDRITIC CELL; DOUBLE STRANDED DNA BREAK; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MONOCYTE; MULTIPLE MYELOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; TUMOR CELL; TUMOR MICROENVIRONMENT;

EID: 84863229246     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-376236     Document Type: Article

References (41)

1. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2(3):175-187. (Pubitemid 37328787)
2. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102(5): 553-563.
3. Nagaoka H, Tran TH, Kobayashi M, Aida M, Honjo T. Preventing AID, a physiological mutator, from deleterious activation: regulation of the genomic instability that is associated with antibody diversity. Int Immunol. 2010;22(4):227-235.
4. Liu M, Duke JL, Richter DJ, et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature. 2008;451(7180):841-845. (Pubitemid 351253166)
5. Ramiro AR, Jankovic M, Eisenreich T, et al. AID is required for c-myc/IgH chromosome translocations in vivo. Cell. 2004;118(4):431-438. (Pubitemid 39485663)
6. Pasqualucci L, Guglielmino R, Houldsworth J, et al. Expression of the AID protein in normal and neoplastic B cells. Blood. 2004;104(10):3318-3325. (Pubitemid 39507152)
7. Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC. The malignant clone and the bonemarrow environment. Best Pract Res Clin Haematol. 2007;20:597-612.
8. Bahlis NJ, King AM, Kolonias D, et al. CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood. 2007;109(11):5002-5010. (Pubitemid 46827800)
9. Said JW, Rettig MR, Heppner K, et al. Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. Blood. 1997;90(11):4278-4282. (Pubitemid 27508433)
10. Chauhan D, Singh AV, Brahmandam M, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009;16(4):309-323.
11. Kukreja A, Hutchinson A, Dhodapkar K, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med. 2006; 203(8):1859-1865. (Pubitemid 44188460)
12. Dhodapkar KM, Barbuto S, Matthews P, et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood. 2008;112(7):2878-2885.
13. Banerjee D, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar K. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after DC injection of cytokine matured DCs in myeloma patients. Blood. 2006;108(8):2655-2661.
14. Dickhout JG, Lhotak S, Hilditch BA, et al. Induction of the unfolded protein response after monocyte to macrophage differentiation augments cell survival in early atherosclerotic lesions. FASEB J. 2011;25:576-589.
15. Lee H, Trott JS, Haque S, McCormick S, Chiorazzi N, Mongini PK. A cyclooxygenase-2/prostaglandin E2 pathway augments activation-induced cytosine deaminase expression within replicating human B cells. J Immunol. 2010; 185(9):5300-5314.
16. Yang C, Betti C, Singh S, Toor A, Vaughan A. Impaired NHEJ function in multiple myeloma. Mutat Res. 2009;660(1-2):66-73.
17. Cheong C, Matos I, Choi JH, et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell. 2010;143(3):416-429.
18. Chauhan D, Bharti A, Raje N, et al. Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. Blood. 1999;93(5):1482-1486. (Pubitemid 29102473)
19. Schoppet M, Henser S, Ruppert V, et al. Osteoprotegerin expression in dendritic cells increases with maturation and is NF-kappaB-dependent. J Cell Biochem. 2007;100(6):1430-1439. (Pubitemid 46515577)
20. Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 2008;1143(11):123-150.
21. Delker RK, Fugmann SD, Papavasiliou FN. A coming-of-age story: activation-induced cytidine deaminase turns 10. Nat Immunol. 2009;10(11): 1147-1153.
22. Hasham MG, Donghia NM, Coffey E, et al. Widespread genomic breaks generated by activationinduced cytidine deaminase are prevented by homologous recombination. Nat Immunol. 2010; 11(9):820-826.
23. Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia. 2010;24(4):679-686.
24. Tucci M, Ciavarella S, Strippoli S, Brunetti O, Dammacco F, Silvestris F. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro. Exp Hematol. 2011;39(7):773-783.e1.
25. Tucci M, Stucci S, Strippoli S, Dammacco F, Silvestris F. Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression? Oncologist. 2011;16(7):1040-1048.
26. Kukreja A, Hutchinson A, Mazumder A, et al. Bortezomib disrupts tumor-dendritic cell interactions in myeloma and lymphoma: therapeutic implications. Br J Haematol. 2006;136(1):106-110. (Pubitemid 44912594)
27. Kukreja A, Radfar S, Sun BH, Insogna K, Dhodapkar MV. Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood. 2009;114(16):3413-3421.
28. Nussenzweig A, Nussenzweig MC. Origin of chromosomal translocations in lymphoid cancer. Cell. 2010;141(1):27-38.
29. Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell. 2008;13(2):167-180. (Pubitemid 351163163)
30. Casellas R, Yamane A, Kovalchuk AL, Potter M. Restricting activation-induced cytidine deaminase tumorigenic activity in B lymphocytes. Immunology. 2009;126(3):316-328.
31. Takizawa M, Tolarova H, Li Z, et al. AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J Exp Med. 2008;205(9): 1949-1957.
32. Palacios F, Moreno P, Morande P, et al. High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. Blood. 2010;115(22):4488-4496.
33. Pauklin S, Sernandez IV, Bachmann G, Ramiro AR, Petersen-Mahrt SK. Estrogen directly activates AID transcription and function. J Exp Med. 2009;206(1): 99-111.
34. Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med. 1999;190(10):1417-1426.
35. Gourzi P, Leonova T, Papavasiliou FN. A role for activation-induced cytidine deaminase in the host response against a transforming retrovirus. Immunity. 2006;24(6):779-786. (Pubitemid 43867362)
36. Ramiro AR, Jankovic M, Callen E, et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature. 2006; 440(7080):105-109. (Pubitemid 43336276)
37. Uhr JW, Pantel K. Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A. 2011; 108(30):12396-12400.
38. Ploemacher RE, Brons NH. The relative spatial distribution of CFU-S in the mouse spleen. Exp Hematol. 1985;13(10):1068-1072. (Pubitemid 16172302)
39. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med. 2003;198(11):1753-1757. (Pubitemid 37494167)
40. Jinushi M, Vanneman M, Munshi NC, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008;105(4):1285-1290. (Pubitemid 351397045)
41. Rozanski CH, Arens R, Carlson LM, et al. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J Exp Med. 2011;208(7):1435-1446.